Arcutis Biotherapeutics, Inc.
ARQT
$26.23
$0.311.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 461.98M | 413.62M | 372.07M | 313.93M | 259.47M |
| Total Other Revenue | 2.00M | 2.00M | 4.00M | 4.00M | 4.00M |
| Total Revenue | 463.98M | 415.62M | 376.07M | 317.93M | 263.47M |
| Cost of Revenue | 41.10M | 37.65M | 36.70M | 31.91M | 28.73M |
| Gross Profit | 422.89M | 377.98M | 339.38M | 286.02M | 234.74M |
| SG&A Expenses | 297.60M | 284.63M | 274.55M | 253.18M | 249.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 429.73M | 412.41M | 388.30M | 356.18M | 349.30M |
| Operating Income | 34.25M | 3.21M | -12.23M | -38.25M | -85.84M |
| Income Before Tax | 29.30M | -1.39M | -14.97M | -43.30M | -92.33M |
| Income Tax Expenses | 779.00K | 985.00K | 1.17M | 1.02M | 944.00K |
| Earnings from Continuing Operations | 28.52 | -2.38 | -16.14 | -44.32 | -93.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.52M | -2.38M | -16.14M | -44.32M | -93.27M |
| EBIT | 34.25M | 3.21M | -12.23M | -38.25M | -85.84M |
| EBITDA | 36.50M | 5.46M | -7.56M | -33.83M | -80.71M |
| EPS Basic | 0.22 | -0.02 | -0.13 | -0.35 | -0.74 |
| Normalized Basic EPS | 0.14 | -0.01 | -0.08 | -0.22 | -0.46 |
| EPS Diluted | 0.21 | -0.04 | -0.15 | -0.36 | -0.75 |
| Normalized Diluted EPS | 0.13 | -0.01 | -0.08 | -0.22 | -0.46 |
| Average Basic Shares Outstanding | 515.76M | 512.24M | 508.91M | 505.58M | 502.26M |
| Average Diluted Shares Outstanding | 533.78M | 524.88M | 521.55M | 510.84M | 502.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |